TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03385928
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given within 2 hours of symptom onset
Study: NCT04181385
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo capsules
Study: NCT00889538
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of 1/2 normal saline IV
Study: NCT00889538
Drug: glutathione
Normalized name: Glutathione
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: glutathione 600 mg IV
Study: NCT00889538
Drug: glutathione, vit C and NAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
Study: NCT00911534
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
Study: NCT00472563
Drug: Bicarbinate 150 mEq/L
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
Study: NCT01589458
Drug: Toothpaste
Normalized name: TOOTHPASTE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
Study: NCT00814294
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsule,0 units, quater in die (QID) for 18 weeks
Study: NCT00814294
Drug: Oral Hepatic Directed Vesicles (HDV)-Insulin (U-15)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HDV-I Caps; 15 U; quater in die (QID) for 18 weeks.
Study: NCT00814294
Drug: Oral Hepatic Directed Vesicles (HDV)-Insulin (U-5)
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral HDV-I; Caps; 5 U; quater in die (QID) for 18 weeks.
Study: NCT04702568
Drug: BCX9930
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCX9930 for oral administration
Study: NCT00908154
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets to match GSK1014802
Study: NCT00908154
Drug: GSK1014802
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium channel blocker
Study: NCT02824133
Drug: AZD4547
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg bd (per os)
Study: NCT03936192
Drug: glucosamine sulphate 1500mg and meloxicam 15mg
Normalized name: glucosamine hydrochloride 1500 MG
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: glucosamine sulphate 1500mg plus meloxicam 15mg, manufactured by Eurofarma Laboratories S.A., administered once a day for 12 weeks.
Study: NCT01543139
Drug: Valproate+Cytidine-+Creatine-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valproate: Week0-8: 300mg/day, Cytidine-: Week0-8: 2g/day, Creatine-: Week0-1: 3g/day Week1-8: 5g/day
Study: NCT00649441
Drug: Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg
Normalized name: hydrochlorothiazide / quinapril
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/25mg, single dose fasting
Study: NCT00649441
Drug: Accuretic™ Tablets 20 mg/25 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20/25mg, single dose fasting
Study: NCT04508725
Drug: Vascular Endothelial Growth Factor Receptor 2 tyrosine kinase inhibitor plus immune checkpoint inhibitor
Normalized name: endothelial growth factor A, vascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive less than 4 weeks of TKI treatment during the first 12 weeks. Plus immune checkpoint inhibitor (arm 1) or non-immune checkpoint inhibitor (arm 2)
Study: NCT03623425
Drug: 18F-FCH PET
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: a 18F-FCH PET exam before the 68Ga-PSMA-11 PET exam
Study: NCT01357980
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra detrusor injection on Day 1 (single dose)
Study: NCT02722265
Drug: CS-3150
Normalized name: MyoGesic-CS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
Study: NCT00440830
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch applied to smokers
Study: NCT00440830
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo patch applied to nonsmokers
Study: NCT02951429
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matched with sildenafil.
Study: NCT00753597
Drug: Solu-medrone, Mabthera
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125mg, 1gram, twice day 1 and day 15
Study: NCT03936192
Drug: Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucosamine sulfate 1500mg and chondroitin sulfate 1200mg, manufactured by Zodiac Pharmaceutical Products S.A. (Condroflex®)
Study: NCT03936192
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once daily for 12 weeks.
Study: NCT03024255
Drug: BBI-4000 gel, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI-4000 gel, 5% applied once to each axilla daily
Study: NCT03024255
Drug: BBI-4000 gel, 10%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI-4000 gel, 10% applied once to each axilla daily
Study: NCT03024255
Drug: BBI-4000 gel, 15%
Approvals — FDA: no, EMA: no, PMDA: no
Description: BBI-4000 gel, 15% applied once to each axilla daily
Study: NCT00597415
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: celecoxib 200mg
Study: NCT00597415
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT00654953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (cellulose or lactose) administered twice per day for 12 weeks.
Study: NCT03597087
Drug: Anesthesia
Normalized name: anesthesia tray
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anaesthesia : propopol~Spinal anaesthesia : bupibacaine
Study: NCT01277497
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate 1,334 mg three times daily with meals for 12 weeks
Study: NCT02283203
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
Study: NCT02836483
Drug: LCB01-0371 800mg, QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02836483
Drug: LCB01-0371 400mg, BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02836483
Drug: LCB01-0371 800mg, BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02836483
Drug: Zyvox 600mg, BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT02044861
Drug: PFK-158
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose escalation
Study: NCT02836483
Drug: LCB01-0371 1200mg, QD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03220334
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control group was treated with normal saline for artificial gastric ulcer after ESD.
Study: NCT01147406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
Study: NCT03867942
Drug: Monolayer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monolayered combination of gemigliptin and rosuvastatin
Study: NCT03867942
Drug: Bilayer group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilayered combination of gemigliptin and rosuvastatin
Study: NCT02597140
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
Study: NCT00417430
Drug: ICI 182,780 (Faslodex)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00333918
Drug: placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01772836
Drug: RPX7009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
Study: NCT01772836
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
Study: NCT03310385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT04839120
Drug: MDPK67b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two subgroups (Panels A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
Study: NCT04839120
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two subgroups (Panel A and Panel B) of four subjects were to be randomly allocated either to placebo or to three increasing doses of MDPK67b, administered as single infusion at intervals of at least two weeks during the first three periods with the last period involving four repeated doses administered at three-day intervals.
Study: NCT01093586
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01770899
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gelatin capsule given every 24 hours
Study: NCT00788710
Drug: etoricoxib (MK0663) 120 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg of etoricoxib (MK0663) for a total of 5 days
Study: NCT00105989
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00788710
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
Study: NCT02159261
Drug: BAY98-7071_EE20/DRSP/L-5-MTHF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients treated by Physicians under approved local prescriptions
Study: NCT02483689
Drug: Pre Incisional Local Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
Study: NCT01185704
Drug: Recombinant Human Choriogonadotropin (r-hCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
Study: NCT00159159
Drug: Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02939599
Drug: QCC374
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.015mg and 0.06mg
Study: NCT00788710
Drug: etoricoxib (MK0663) 90 mg
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mg of etoricoxib (MK0663) for a total of 5 days
Study: NCT03082053
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Companion Medication
Study: NCT03908970
Drug: 1% OPA-15406
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT03908970
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT02839941
Drug: Glucocorticoids
Normalized name: GLUCOCORTICOIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive glucocorticoids for consecutive 52 weeks
Study: NCT03154541
Drug: Synrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-CF Cohort The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.~CF Cohort The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse.
Study: NCT02741219
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Group receives normal saline bolus after delivery
Study: NCT02741219
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sufentanil PCA after surgery
Study: NCT02741219
Drug: Sufentanil and dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufentanil combined with dexmedetomidine PCA after surgery
Study: NCT02133742
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
Study: NCT02235402
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02472795
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule of cenerimod to be taken once daily, irrespective of food intake. The capsule is to be swallowed whole. The capsule should be taken each day at approximately the same time (preferably each morning).
Study: NCT02192502
Drug: human albumin 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00475800
Drug: Lumiracoxib
Normalized name: Lumiracoxib
DrugBank: Lumiracoxib (DB01283)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03812588
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo (or dummy pill) is an inert (inactive) substance, typically a tablet, capsule or other dose form that does not contain an active drug ingredient.
Study: NCT01725256
Drug: AIR001 (sodium nitrite inhalation solution)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose arms specify dose loaded into the I-neb AAD System nebulizer
Study: NCT00003893
Drug: CMF regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00003893
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003893
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003893
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003893
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01392378
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
Study: NCT01392378
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
Study: NCT00788697
Drug: SonoVue-enhanced ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
Study: NCT00108797
Drug: Feiba VH
Normalized name: Feiba VH Immuno
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02564029
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for PF-06372865 and placebo for lorazepam
Study: NCT03627494
Drug: GSK3439171A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral solution with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Study: NCT03627494
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral solution to match with doses 0.5 mg up to 4.5 mg and capsule for doses 5 mg and upwards
Study: NCT03649334
Drug: ketamine-ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patient will receive ketamine 0.5mg.kg-1 + ketorolac 1mk.kg-1 in 2 ml syringe intramuscularly.
Study: NCT03649334
Drug: fentanyl- ketorolac
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The patient will receive fentanyl 1.5ug.kg-1 + ketorolac 1 mg.kg-1 in 2ml syringe intramuscularly
Study: NCT03686696
Drug: Beta blocker
Normalized name: Beta blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to beta-blockade will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
Study: NCT03686696
Drug: ACEI
Normalized name: Veneno de Abeja Aceite de Vibora
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to ACE inhibitor will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications.
Study: NCT03686696
Drug: ARB
Normalized name: Arbli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized to Angiotensin receptor blockers will be administered the assigned treatment during the rest of the hospital stay and receive a prescription for the continued use at discharge. The treating physician is encouraged to aim for target dose or highest tolerable dose for the drug. Patients will be encouraged to continue the use of the randomized treatment following discharge until contraindications
Study: NCT01255306
Drug: Local medical treatment of raised intraocular pressure
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:~Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added.
Study: NCT03199638
Drug: Glutamine vs. Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral supplementation with either glutamine or placebo twice daily for 3 months
Study: NCT04939792
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule ingested orally
Study: NCT04939792
Drug: Vitamin D + L-cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule ingested orally
Study: NCT02792517
Drug: Ethynil Estradiol/Norgestimate Oral Contraceptive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethynil estradiol (EE)/norgestimate combination oral contraceptive is a 28-tablet cycle in which 1 oral tablet is taken daily; each containing 0.250 mg norgestimate and 0.035 mg EE for 21 days, after which a tablet only containing inert ingredients is taken for last 7 days of the 28 day cycle.
Study: NCT00798577
Drug: Vigamox Ophthalmic Solution
Normalized name: Vigamox Ophthalmic Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 5mg/mL 3 times daily for 7 days
Study: NCT00798577
Drug: BSS placebo
Normalized name: BSS Ophthalmic Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
Study: NCT01412060
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied in capsules.
Study: NCT03097029
Drug: Pancreatic Enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
Study: NCT02807844
Drug: MCS110
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
Study: NCT02807844
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: MCS110 and PDR001 - for administration once every 3 weeks via i.v. infusion.
Study: NCT02192502
Drug: HES 130/0.4 (Voluven)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00629525
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAD001 at a dose of 10 mg PO daily
Study: NCT00661102
Drug: Corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00661102
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00661102
Drug: capecitabine [Xeloda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00661102
Drug: dexpantenol [Bepantol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: As prescribed
Study: NCT00753688
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo 800 mg once daily orally